Evidence map›Paper›PMID 39516318›Full record

ArticleScientific reports2024

Prognostic value of serum complement cleavage factor Bb in idiopathic membranous nephropathy and establishment of nomogram model.

Lu Wen, Qianqian Li, Genyang Cheng, Yuan Zhang, Zhanzheng Zhao

Abstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Hyperlipidemia in membranous nephropathy.Clinical kidney journal · 2026
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Lu WenDepartment of Nephrology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China. wenlu2010@hotmail.com.
Qianqian LiDepartment of Nephrology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.
Genyang ChengDepartment of Nephrology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.
Yuan ZhangSchool of Physics and Laboratory of Zhongyuan Light, Zhengzhou University, Zhengzhou, 450052, China.
Zhanzheng ZhaoDepartment of Nephrology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Complement activation is involved in idiopathic membranous nephropathy (IMN). We aimed to investigate the relationship of serum complement cleavage factor Bb with IMN progression, and to establish a model for early prediction of kidney outcomes. We measured serum factor Bb in a retrospective cohort of 449 IMN patients at the time of kidney biopsy. Cox regression analysis showed that higher levels of serum factor Bb were independently associated with IMN progression event defined as end-stage renal disease or ≥ 40% decline in estimated glomerular filtration rate. Patients in the middle and highest tertiles of serum factor Bb had respectively 2.1-, and 2.6-fold higher risk for disease progression compared with those in the lowest tertile. We developed an optimized prognostic nomogram model incorporating age, log serum anti-PLA2R antibody, log serum Bb, proteinuria and tubular atrophy/interstitial fibrosis. The model demonstrated good predictive ability with a concordance index of 0.77 (bootstrap-corrected of 0.76) for predicting 3-, and 5-year kidney survival. Calibration curves and decision curve analysis confirmed the model's good calibration and clinical utility. Our findings suggest that serum factor Bb may serve as an essential prognostic indicator of IMN. The novel nomogram model may offer important guidance on the management of this patient population.

Indexed as

Complement Factor BGlomerulonephritis, MembranousNomogramsAdultAgedBiomarkersDisease ProgressionFemaleGlomerular Filtration RateHumansKidney Failure, ChronicMaleMiddle AgedPrognosisReceptors, Phospholipase A2Retrospective StudiesBiomarkersComplement Factor BPLA2R1 protein, humanReceptors, Phospholipase A2

Identifiers

PMID39516318
PMCPMC11549282

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.